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Abstract
Palliation of pain with morphine in cancer patients can be complicated by adverse effects. Tolerance
to these effects such as nausea and drowsiness usually occurs within a few days allowing
continuation of morphine therapy. However, some patients may develop intolerable adverse
effects even after several months on morphine when the dose is increased. A case of morphine-
induced hallucinations in a cancer patient who had been on a subcutaneous infusion of diamorphine
for several months is discussed. A switch to oxycodone resolved his hallucinations and gave him a
new lease of life. The theories behind and evidence for opioid-switching is discussed along with
strategies for dealing with intolerable opioid-induced adverse effects.
Case presentation
A 73-year-old British Caucasian gentleman, had been
diagnosed with prostate cancer one year previously and
was on hormone therapy. Three months after diagnosis,
he was found to have a rising PSA (prostate specific anti-
gen) and ALP (alkaline phosphatase) as well as pain in his
right hip. A bone scan revealed bone metastases. Radio-
therapy made no difference to the hip pain. He then tried
a variety of analgesics from the family doctor including a
NSAID (non-steroidal anti-inflammatory drug) and oral
morphine but adequate dosing was hindered by nausea
and vomiting.
He was eventually referred to a palliative care physician
who commenced him on a subcutaneous infusion of
diamorphine 20 mg and cyclizine 15 0 mg over 24 hours.
This controlled the nausea and eased the pain although
not completely.
The patient was then referred for hospice admission for
respite and further symptom control. An increase in
diamorphine to 30 mg over 24 hours in the syringe driver
gave him good pain control. As he was doing so well, a
trial of oral morphine and cyclizine was initiated. How-
ever, the nausea and vomiting recurred within a few hours
and so he was recommenced on the syringe-driver, again
with good effect. He was then discharged.
The patient had been reasonably symptom-controlled the
first 3 weeks after discharge. Unfortunately he had then
become unwell with diarrhoea and had experienced more
pain. The family doctor increased the diamorphine to 50
mg in the syringe driver to control both the diarrhoea
(which resolved) and the pain. However, he then became
nauseated. As a result, the anti-emetic was changed to
haloperidol 5 mg and then to levomepromazine (nozi-
nan) 12.5 mg which still did not control his nausea. By
then, the patient was also experiencing frightening hallu-
cinations and he and his wife were finding it very hard to
cope at home. The hospice at home team were providing
bolus injections of nozinan for the nausea and hallucina-
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tions but these seemed to have little effect. He was then re-
admitted to the hospice for symptom control.
Initial assessment revealed signs of opioid toxicity includ-
ing meiosis and myoclonic jerks. The symptoms of nausea
and hallucinations were also consistent with opioid toxic-
ity. The patient appeared to be pain-controlled. The initial
management was therefore to decrease the diamorphine
in the syringe driver back down to 30 mg over 24 hours.
Recent blood test results were obtained which revealed
normal renal function, full blood count and calcium
although liver function tests were abnormal indicating
probable liver metastases and therefore disease progres-
sion. The hallucinations resolved completely and the nau-
sea settled down with this reduction in diamorphine.
Over the next few days, the patient felt that his pain wasn't
optimally controlled and so the diamorphine was cau-
tiously increased again, this time to 40 mg over 24 hours.
Initially, the vomiting recurred as a result of this change
but not the hallucinations. The nozinan was increased to
50 mg to control the nausea but the patient went on to
develop itch and hallucinations. He became agitated, con-
fused with fluctuating conscious level, stopped eating and
drinking and became bed-bound. He also had a disturbed
sleep-wake cycle. These are the features of delirium as
required by the ICD-10 (International Classification of
Diseases, 10th revision, WHO 1993). The differential diag-
noses at this point included delirium secondary to opioid
toxicity and delirium as a feature of pre-terminal agita-
tion. In favour of the former were his known sensitivity to
morphine as evidenced by the previous improvement in
his symptoms with dose reduction. In favour of the latter
were his weight loss (cancer cachexia) noted since his pre-
vious admission and the deterioration in his blood tests
(liver function) indicating liver metastases. There was no
evidence of sepsis, hypoxia, drug interaction or other co-
morbidities that could account for the delirium.
The diamorphine 40 mg was then switched to oxycodone
30 mg and within 24 hours the hallucinations, agitation
and nausea resolved. Over the next few days, he continued
to improve. The nozinan in the syringe driver was reduced
to a less sedative dose and he went home 10 days after the
opioid switch. He felt he had his quality of life back - "I
feel alive again" and enjoyed the next 3 months, which
included Christmas at home with his family.
Discussion
This case illustrates the potential for morphine to cause
intolerable side-effects which can be resolved by a switch
to an alternative opioid. As delirium in cancer patients can
be secondary to a variety of causes (Table 1), it is impor-
tant to consider opioid-induced delirium in the differen-
tial diagnosis. A single patient may have one or more co-
morbidities that mimic opioid-induced adverse effects.
His liver function was abnormal and symptoms of drow-
siness, cognitive impairment, nausea, vomiting and myo-
clonus are all seen in liver failure. However, this is
uncommon in metastatic disease alone unless there are
very extensive hepatic metastases or biliary obstruction.
Cherny et al (2001) reported on the recommendations of
the Expert Working Group of the European Association of
Palliative Care on the management of the Adverse Effects
of oral morphine [1]. As the principles are the same, these
recommendations could be applied to subcutaneous mor-
phine or diamorphine or indeed any other opioid causing
adverse effects. The box below summarises their recom-
mendations.
• Careful evaluation to distinguish between mor-
phine-induced adverse effects from co-morbidities
that mimic these effects.
￿ Consider reduction in dose of morphine +/- adding
in co-analgesics or treatments targeting the specific
pain syndrome (such as radiotherapy).
￿ Symptomatic management of the adverse effect
using neuroleptics such as haloperidol or benzodi-
azepines such as midazolam.
Table 1: Co-morbidities that cause cognitive impairment and hallucinations
Metabolic Hypoxia, hypercalcaemia, hyponatraemia, renal failure, liver failure, dehydration
Drug-induced Opioids, benzodiazepines, tricyclics, corticosteroids, chemotherapy, drug withdrawal
Recreational drugs Including alcohol and alcohol withdrawal
Infection Particularly Urinary Tract Infection in the elderly
CNS Cerebral metastases, Leptomeningeal metastases, cerebrovascular incident, head injury
Terminal phase Pre-terminal agitation is a recognised phenomenonCases Journal 2009, 2:9391 http://www.casesjournal.com/content/2/1/9391
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￿ Switching the route of opioid administration -
though the authors point out there is no strong evi-
dence for this.
￿ Opioid switching such as from morphine to oxyco-
done, fentanyl or methadone, thus reducing the risks
of polypharmacy.
Applying the above strategy to his case, other causes for
delirium were initially sought, and a dose reduction of
morphine was made. Co-analgesia with diclofenac (a
NSAID) had already been tried with little effect on overall
pain control as had radiotherapy which had also made no
difference. When adverse effects recurred as the morphine
dose was increased, symptomatic management of these
effects with nozinan and midazolam was attempted.
When this strategy failed, a switch in opioid to oxycodone
produced dramatic improvement. Considering an opioid
switch earlier in the patient management would have, in
hindsight, been less traumatic for both the patient and his
family. It may be a better strategy to perhaps switch opio-
ids if adverse effects are not subsiding within 48 hours and
are causing distress to the patient. A study by Bruera et al
(1995) showed a reduction in the incidence of delirium in
cancer patients on opioids and a reduction in the use of
drugs to manage this adverse effect when a policy of cog-
nitive monitoring, hydration and opioid switching was
introduced [2].
Most experts, including Hanks et al (2005) in the Oxford
Textbook of Palliative Medicine, agree that tolerance to
the common adverse effects of opioids such as nausea,
sedation and mild cognitive impairment occurs within
days [3]. It is therefore established practice to forewarn
and forearm the patient prior to initiating or increasing
the dose of opioids that these side effects are to be
expected and are usually transient. Anti-emetics are usu-
ally co-prescribed. However, CNS-excitatory adverse
effects such as delirium, hallucinations and myoclonus
may have a dose-response relationship and a chronicity-
response relationship to morphine. According to expert
opinion, prolonged exposure to morphine decreases the
tendency to develop sedation and respiratory depression
but increases the tendency to delirium and myoclonus. In
a small proportion of patients, the common side effect of
nausea continues to be a problem. In this case, nausea sec-
ondary to morphine was a continuing problem, only
really controlled when morphine (in the form of diamor-
phine) and an anti-emetic was administered via the sub-
cutaneous route. When the dose of diamorphine was
increased, the nausea recurred and could not be control-
led with anti-emetics. The patient had been on diamor-
phine for some months when the adverse effects of
delirium and myoclonus occurred and there certainly was
a dose-response relationship to these effects.
The evidence for opioid switching
A report of five cases by Galer et al (1992), demonstrated
the inter-individual variability in response to different
opioids [4]. In all five cases, a switch to an alternative opi-
oid resulted in better pain control and reduction of intol-
erable side-effects. They suggested that a person's response
to opioids is dependent on a number of variables:
(1) Pain characteristics (eg. neuropathic, bone)
(2) Drug characteristics (eg. pharmacokinetic and phar-
macodynamic properties, interaction with other drugs)
(3) Individual characteristics (eg. age, genetic variation in
receptor subtypes, co-morbidities)
Pain characteristics
It is universally acknowledged that the analgesia needs to
target the pain syndrome. For instance neuropathic pain is
not always opioid-responsive and co-analgesics may obvi-
ate the need for dose escalation of opioid.
Drug characteristics
The metabolism of morphine is via the UGT (uridine-
diphosphoglyceryl transferase) system in the liver where
the active metabolites M6G (morphine 6-glucuronide)
and M3G (morphine 3-glucuronide) are produced. M6G
has been shown to accumulate in renal failure and has
been implicated in toxicity. M3G has been implicated in
causing opioid-induced hyperalgesia and convulsions and
is known to accumulate in cerebrospinal fluid in rodent
studies. Extrapolating from this, it may be that M3G may
be responsible for other neuroexcitatory effects such as
hallucinations and myoclonus. de Stoutz et al (1995)
based their study of 191 cancer patients treated with mor-
phine, on the hypothesis that morphine metabolites were
involved in the development of dose-limiting toxicity [5].
42% of these patients required opioid switching.
Oxycodone like codeine, on the other hand, is metabo-
lized in the liver by the enzyme cytochrome P450 2D6
(CYP2D6) to oxymorphone and by N-demethylation to
noroxycodone, although it is oxycodone that is mostly
responsible for both side effects and analgesia. It is postu-
lated that the differences in metabolism of opioids may,
in part, account for the differences in incidence of adverse
effects and development of tolerance to these effects. A
more detailed account of the pharmacological basis for
opioid switching is to be found in the paper by Ross et al
[6].
Different opioids bind differently to the opioid receptors.
Morphine, oxycodone, methadone and fentanyl, are all μ
opioid receptor agonists. Oxycodone also acts on the κCases Journal 2009, 2:9391 http://www.casesjournal.com/content/2/1/9391
Page 4 of 5
(page number not for citation purposes)
opioid receptor. These differences may also play a part in
response to opioids.
Individual characteristics
Riley et al (2004) conducted a retrospective study which
aimed to identify individual characteristics including hae-
matological and biochemical parameters that could pre-
dict morphine intolerance and the need for opioid
switching [7]. They identified age > 78 years, high white
cell count (>7 × 109/l), high platelet count (>210 × 109/l)
and poor renal or liver function as important predictors.
The patient only fell into the last category with an ALP of
844 iu/l and an ALT of 451 iu/l.
Inter-individual genetic variation in the genes coding for
CYP2D6 and other enzymes involved in drug metabolism
may account for inter-individual differences in response
to opioids. It is well-established that polymorphisms in
the gene for CYP2D6 can lead to poor metabolism of
codeine to its active metabolite morphine. 5-10% of Cau-
casians lack these enzymes. Maddocks et al (1996) con-
ducted a study evaluating the effect on morphine-induced
delirium by switching to subcutaneous infusion of oxyco-
done [8]. He identified whether these patients were poor
metabolizers or not through the dextromethorphan test.
Unsurprisingly, the poor metabolizer identified required
higher doses of oxycodone. Overall, his study of 13
patients found that a switch to oxycodone significantly
improved mental state.
According to Ross et al (2006), genetic variation leading
to variation in opioid receptor morphology and subse-
quently drug binding, could account for inter-individual
differences [6]. Polymorphisms in the gene for the μ-opi-
oid receptor can, in theory, alter the affinities of different
opioids to the receptor. However, this needs further study
as there is conflicting evidence thus far. Studies on human
post-mortem brain samples reveal the wide inter-individ-
ual variation in the densities of the μ-opioid receptors
which again could contribute to inter-individual differ-
ences in response to opioids.
Ross et al (2006) also discuss the role of other genes such
as the MDR-1 gene which codes for P-glycoprotein, a
membrane-bound transporter protein that regulates drug
absorption and excretion [6]. In P-glycoprotein knockout
mice, high CNS concentrations of morphine, fentanyl and
methadone were measured. Likewise, similar experiments
on mice revealed the critical role of other proteins such as
β-arrestin-2, an intracellular protein that regulates recep-
tor desensitization and internalization. The analgesic
effect of morphine was found to be prolonged in knock-
out mice. Polymorphisms in these genes in human sub-
jects would therefore be expected to influence individual
responses to drugs.
Oxycodone as the second-line opioid
Cairns (2001) reviewed the studies evaluating the use of
oxycodone compared with morphine and concluded that
the analgesic effects were comparable but that a switch to
oxycodone should be considered in patients experiencing
intolerable side-effects such as hallucinations [9]. How-
ever, there are no randomised controlled trials to support
the use of oxycodone as opposed to morphine and the
studies thus far were inadequately powered with small
numbers of patients.
Since then, Riley et al (2006) conducted a study of 186
cancer patients treated with oral morphine for cancer
pain, and found that 25% experienced either intolerable
side-effects or inadequate pain relief and needed a switch
in opioid [10]. Oxycodone was used as the second-line
opioid and 79% of non-responders to morphine had their
pain and adverse effects successfully controlled by oxyco-
done. This evidence further strengthens the case for oxyco-
done as the second-line opioid of choice. In addition, its
availability in both IR and MR preparations and as a sub-
cutaneous injection makes its use more practicable than
fentanyl or methadone. These latter opioids also play
important roles in pain-control, particularly in patients
with renal failure in the case of fentanyl and neuropathic
pain in the case of methadone, and also would be ideal
candidates as third-line and fourth-line opioids in the
management of inadequate pain relief and adverse effects
from morphine and oxycodone. A small study by McNa-
mara (2002) found there was an improvement in cogni-
tive function when patients were switched from morphine
to transdermal fentanyl [11]. Indelicato and Portenoy
(2003) describe the case of a cancer patient with intracta-
ble, worsening pain, no longer controlled by morphine
who rotated to several different opioids including fenta-
nyl and oxycodone, but eventually found pain relief with
a switch to methadone [12].
Conclusion
In the treatment of cancer patients experiencing hallucina-
tions, cognitive impairment and/or nausea, it is important
to consider morphine-induced adverse effects as a cause,
after excluding co-morbidities that may mimic these
symptoms. A patient can develop CNS-excitatory side
effects even after many months of morphine use, particu-
larly when the dose is increased. A switch to oxycodone
must be considered if symptoms do not subside or are not
easily controlled, sooner rather than later, particularly if
the patient is very distressed by the adverse effects.
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